Influenza Diagnostics Market Size to grow by USD 517.5 million between 2024-2028
According to a research report “ Influenza Diagnostics Market” by End-user (Hospitals and diagnostic laboratories, Academic and research centers, Homecare) Type (Point-of-care testing, Immunodiagnostics, Molecular diagnostics) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 517.5 million, at a CAGR of 7.22% during the forecast period. The influenza virus poses a substantial health concern, with the Centers for Disease Control and Prevention (CDC) estimating 360,000 to 750,000 hospitalizations in the US alone during the 2023-2024 season. Given the seasonal nature of influenza, with outbreaks typically occurring during colder months, there is a consistent demand for accurate and efficient diagnostic testing solutions. This need intensifies during influenza outbreaks, as early detection and appropriate management are crucial to mitigate the impact of the virus on public health. Consequently, the influenza diagnostics market experiences significant growth to meet the escalating testing requirements..
Browse market data tables, figures, and in-depth TOC on “Influenza Diagnostics Market” by End-user (Hospitals and diagnostic laboratories, Academic and research centers, Homecare) Type (Point-of-care testing, Immunodiagnostics, Molecular diagnostics) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By End-user, the Hospitals and diagnostic laboratories segment is projected to dominate the market size in 2024
The hospital and diagnostic laboratories segment represents a significant portion of the global influenza diagnostics market. Influenza diagnostics encompasses tests and procedures designed to identify and confirm influenza infections in individuals. This segment specifically caters to the utilization of influenza diagnostic tools within hospitals and diagnostic laboratories. Influenza, a highly contagious respiratory illness, affects millions annually. Hospitals and laboratories manage a substantial number of influenza cases, necessitating efficient and accurate diagnostic solutions. These institutions prioritize prompt diagnosis and effective management of influenza cases to ensure optimal patient care.
By Type, Point-of-care testing segment is expected to hold the largest market size for the year 2024
Point-of-care (POC) influenza diagnostics refer to tests conducted at or near the patient, delivering swift results for immediate clinical decision-making. These tests, which can detect the presence of influenza viruses in patient samples within minutes, are crucial for effective infection management. POC influenza diagnostics employ advanced technologies such as immunoassays, molecular diagnostics, and nucleic acid amplification techniques. The expeditious turnaround time enables healthcare professionals to initiate prompt treatment plans and implement infection control measures. These tests are commonly administered at various healthcare settings, including patient bedside, physician offices, clinics, and emergency departments.
North America is forecasted to hold the largest market size by region in 2024
The Influenza Diagnostics Market represents a significant business opportunity for industry participants, driven by the increasing demand for accurate and rapid influenza diagnoses. This market is characterized by the introduction of advanced technologies, such as molecular diagnostic tests and point-of-care devices, which offer faster results and higher accuracy rates compared to traditional methods. Additionally, the ongoing COVID-19 pandemic has highlighted the importance of early and accurate diagnosis, further boosting market growth. Market size is projected to expand at a robust CAGR during the forecast period.
The Influenza Diagnostics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Influenza Diagnostics Market encompasses various diagnostic tools used by healthcare providers to identify and confirm influenza infections. This market includes Rapid Antigen Tests and Molecular Diagnostics, such as Polymerase Chain Reaction (PCR) and Reverse Transcription-Polymerase Chain Reaction (RT-PCR), used in hospitals and clinics, diagnostic laboratories, research industries, and medical sector. Traditional diagnostic tests, like Serology tests and Viral Culture tests, are also part of this market. The regulatory framework for influenza diagnostics is stringent due to the potential for false-positive and false-negative results, which can impact patient treatment and interventions. Sensitivity and specificity are crucial factors in evaluating diagnostic tools' performance. Healthcare professionals rely on these diagnostic technologies to diagnose influenza infections, which can lead to severe illness and respiratory deaths. The World Health Organization recommends the use of Rapid Diagnostic Tests for influenza to improve patient care and reduce the burden on healthcare systems. The Influenza Diagnostics Market is segmented based on product types, applications, and end-users. The market's growth is driven by the increasing demand for accurate and rapid diagnostic tests, technological advancements, and the need to reduce the spread of influenza infections.
Market Research Overview
The Influenza Diagnostics Market encompasses various diagnostic tools used by healthcare providers to identify influenza viruses and other respiratory pathogens. This market includes Rapid Antigen Tests (RATs) and Molecular Diagnostics, such as Polymerase Chain Reaction (PCR) and other molecular diagnostic assays. Hospitals and clinics, diagnostic laboratories, research industries, and primary care offices are major end-users. Traditional diagnostic tests, including serology tests and viral culture tests, are being gradually replaced by more accurate and faster diagnostic technologies. The regulatory framework for influenza diagnostics is stringent, ensuring the accuracy and reliability of these diagnostic tools. False-positive and false-negative results can lead to misdiagnosis and inappropriate treatment, highlighting the importance of sensitivity and specificity in diagnostic tests. Product segmentation includes antigen tests, serological assays, viral culture, molecular diagnostic assays, and multiplex assays. The prevalence of influenza and the burden of respiratory infections necessitate continuous advancements in diagnostic technologies. Public health measures, treatment interventions, and healthcare professionals rely on these diagnostic tools to mitigate infection, severe illness, and respiratory deaths. The World Health Organization (WHO) advocates for the use of rapid diagnostic tests to improve influenza surveillance and response.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
